376 related articles for article (PubMed ID: 34525183)
21. Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative case and review of the literature.
Major A; Collins J; Craney C; Heitman AK; Bauer E; Zerante E; Stock W; Bishop MR; Jasielec J
Leuk Lymphoma; 2021 Jul; 62(7):1765-1769. PubMed ID: 33559517
[No Abstract] [Full Text] [Related]
22. Imaging-based Toxicity and Response Pattern Assessment Following CAR T-Cell Therapy.
Smith DA; Kikano E; Tirumani SH; de Lima M; Caimi P; Ramaiya NH
Radiology; 2022 Feb; 302(2):438-445. PubMed ID: 34751616
[TBL] [Abstract][Full Text] [Related]
23. T-cell activation profiles distinguish hemophagocytic lymphohistiocytosis and early sepsis.
Chaturvedi V; Marsh RA; Zoref-Lorenz A; Owsley E; Chaturvedi V; Nguyen TC; Goldman JR; Henry MM; Greenberg JN; Ladisch S; Hermiston ML; Jeng M; Naqvi A; Allen CE; Wong HR; Jordan MB
Blood; 2021 Apr; 137(17):2337-2346. PubMed ID: 33512385
[TBL] [Abstract][Full Text] [Related]
24. Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.
Acharya UH; Dhawale T; Yun S; Jacobson CA; Chavez JC; Ramos JD; Appelbaum J; Maloney DG
Expert Rev Hematol; 2019 Mar; 12(3):195-205. PubMed ID: 30793644
[TBL] [Abstract][Full Text] [Related]
25. COVID-19-associated cytokine storm syndrome and diagnostic principles: an old and new Issue.
Yongzhi X
Emerg Microbes Infect; 2021 Dec; 10(1):266-276. PubMed ID: 33522893
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
[TBL] [Abstract][Full Text] [Related]
27. Is COVID-19-associated cytokine storm distinct from non-COVID-19 secondary hemophagocytic lymphohistiocytosis?
Liu JM; Chi J
Exp Biol Med (Maywood); 2022 Feb; 247(4):330-337. PubMed ID: 35068219
[TBL] [Abstract][Full Text] [Related]
28. HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL.
McNerney KO; Si Lim SJ; Ishikawa K; Dreyzin A; Vatsayan A; Chen JJ; Baggott C; Prabhu S; Pacenta HL; Philips C; Rossoff J; Stefanski HE; Talano JA; Moskop A; Verneris M; Myers D; Karras NA; Brown P; Bonifant CL; Qayed M; Hermiston M; Satwani P; Krupski C; Keating AK; Baumeister SHC; Fabrizio VA; Chinnabhandar V; Egeler E; Mavroukakis S; Curran KJ; Mackall CL; Laetsch TW; Schultz LM
Blood Adv; 2023 Jun; 7(12):2758-2771. PubMed ID: 36857419
[TBL] [Abstract][Full Text] [Related]
29. Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T).
Alvi RM; Frigault MJ; Fradley MG; Jain MD; Mahmood SS; Awadalla M; Lee DH; Zlotoff DA; Zhang L; Drobni ZD; Hassan MZO; Bassily E; Rhea I; Ismail-Khan R; Mulligan CP; Banerji D; Lazaryan A; Shah BD; Rokicki A; Raje N; Chavez JC; Abramson J; Locke FL; Neilan TG
J Am Coll Cardiol; 2019 Dec; 74(25):3099-3108. PubMed ID: 31856966
[TBL] [Abstract][Full Text] [Related]
30. Peripheral Blood Smears Distinguish Infective Fever after CAR-T Therapy.
He S; Peng J; Yang X; Meng F; Huang L; Huang L; Tian W; Gao Z; Zhao J; Wang Z; Wei J
Front Biosci (Landmark Ed); 2023 Nov; 28(11):299. PubMed ID: 38062808
[TBL] [Abstract][Full Text] [Related]
31. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management.
Brudno JN; Kochenderfer JN
Blood Rev; 2019 Mar; 34():45-55. PubMed ID: 30528964
[TBL] [Abstract][Full Text] [Related]
32. Hemophagocytic lymphohistiocytosis: a review inspired by the COVID-19 pandemic.
Soy M; Atagündüz P; Atagündüz I; Sucak GT
Rheumatol Int; 2021 Jan; 41(1):7-18. PubMed ID: 32588191
[TBL] [Abstract][Full Text] [Related]
33. Complete spectrum of adverse events associated with chimeric antigen receptor (CAR)-T cell therapies.
Yang C; Nguyen J; Yen Y
J Biomed Sci; 2023 Oct; 30(1):89. PubMed ID: 37864230
[TBL] [Abstract][Full Text] [Related]
34. Ruxolitinib mitigates steroid-refractory CRS during CAR T therapy.
Pan J; Deng B; Ling Z; Song W; Xu J; Duan J; Wang Z; Chang AH; Feng X; Tan Y
J Cell Mol Med; 2021 Jan; 25(2):1089-1099. PubMed ID: 33314568
[TBL] [Abstract][Full Text] [Related]
35. Chimeric antigen receptor T cell therapy and nephrotoxicity: From diagnosis to treatment strategies.
Zhou H; Yang M; Cui L; Jiang J
Int Immunopharmacol; 2020 Dec; 89(Pt B):107072. PubMed ID: 33059198
[TBL] [Abstract][Full Text] [Related]
36. [Natural killer cell cytotoxic activity in critical pediatric patients with suspected hemophagocytic syndrome].
Martínez I; Fernández L; Valentín J; Castillo C; Chamorro C; Pérez-Martínez A
Med Intensiva; 2015 May; 39(4):213-21. PubMed ID: 25081072
[TBL] [Abstract][Full Text] [Related]
37. Free interleukin-18 is elevated in CD22 CAR T-cell-associated hemophagocytic lymphohistiocytosis-like toxicities.
Rocco JM; Inglefield J; Yates B; Lichtenstein DA; Wang Y; Goffin L; Filipovic D; Schiffrin EJ; Shah NN
Blood Adv; 2023 Oct; 7(20):6134-6139. PubMed ID: 37389815
[No Abstract] [Full Text] [Related]
38. Natural Killer Cell Function Tests by Flowcytometry-Based Cytotoxicity and IFN-γ Production for the Diagnosis of Adult Hemophagocytic Lymphohistiocytosis.
Lee H; Kim HS; Lee JM; Park KH; Choi AR; Yoon JH; Ryu H; Oh EJ
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31671661
[TBL] [Abstract][Full Text] [Related]
39. Down-regulation of CD5 expression on activated CD8+ T cells in familial hemophagocytic lymphohistiocytosis with perforin gene mutations.
Wada T; Sakakibara Y; Nishimura R; Toma T; Ueno Y; Horita S; Tanaka T; Nishi M; Kato K; Yasumi T; Ohara O; Yachie A
Hum Immunol; 2013 Dec; 74(12):1579-85. PubMed ID: 24051121
[TBL] [Abstract][Full Text] [Related]
40. Extracorporeal cytokine removal in severe CAR-T cell associated cytokine release syndrome.
Stahl K; Schmidt BMW; Hoeper MM; Skripuletz T; Möhn N; Beutel G; Eder M; Welte T; Ganser A; Falk CS; Koenecke C; David S
J Crit Care; 2020 Jun; 57():124-129. PubMed ID: 32113143
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
